IRVINE, Calif., April 20, 2017 -- Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Invuity, Inc. (“Invuity” or the “Company”) (Nasdaq:IVTY). Investors who purchased or otherwise acquired shares between July 19, 2016 and November 3, 2016, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the April 28, 2017 lead plaintiff motion deadline.
If you purchased Invuity shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the Complaint, during the Class Period, Invuity issued materially false and/or misleading statements about its operations and results and misrepresented its ability to sustain its average revenue per account. On November 3, 2016, Invuity revealed its financial results for its third quarter of 2016, lowering its guidance and noting a drop in average revenue per account.
If you wish to learn more about this lawsuit, or if you have any questions regarding this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]


Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth
Google Secures Pentagon AI Deal for Classified Projects
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 



